Poseida Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Cash & Equivalents	49.34	44.47	81.38	206.33	83.97	87.78
Short-Term Investments	181.51	167.73	201.12	-	225.19	37.53
Cash & Short-Term Investments	230.85	212.2	282.49	206.33	309.15	125.32
Cash Growth	-3.34%	-24.88%	36.92%	-33.26%	146.69%	312.30%
Receivables	14.75	9.01	9.09	-	-	-
Prepaid Expenses	5.1	1.5	2	2.71	2.58	0.88
Other Current Assets	-	3.76	4.98	4.84	2.26	0.98
Total Current Assets	250.7	226.48	298.56	213.87	314	127.18
Property, Plant & Equipment	36.42	40.78	46.67	48.23	48.32	10.86
Goodwill	4.23	4.23	4.23	4.23	4.23	4.23
Other Intangible Assets	1.32	1.32	1.32	1.32	1.32	1.32
Other Long-Term Assets	0.91	1.08	1.06	1.66	3.62	3.41
Total Assets	293.58	273.89	351.84	269.31	371.48	147
Accounts Payable	5.2	3.27	2.23	8.96	0.76	4.93
Accrued Expenses	25.37	27.7	22.18	21.05	22.62	12.26
Current Portion of Long-Term Debt	-	-	-	-	-	3
Current Portion of Leases	6.09	5.95	5.87	6.34	4.81	-
Current Unearned Revenue	37.27	31.01	19.72	4.5	-	-
Other Current Liabilities	4.34	3.4	3.89	2.49	1.84	1.67
Total Current Liabilities	78.27	71.32	53.89	43.34	30.03	21.86
Long-Term Debt	58.91	58.59	58.25	29.36	31.63	28.64
Long-Term Leases	17.73	20.88	24.64	25.5	25.37	-
Long-Term Unearned Revenue	48.4	16.78	25.33	13.26	23.76	19.59
Long-Term Deferred Tax Liabilities	-	-	-	0.06	0.06	0.06
Other Long-Term Liabilities	3.05	2.61	2.15	1.59	-1.33	2.92
Total Liabilities	206.37	170.18	164.24	113.1	109.52	73.06
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	716.53	697.86	658.6	563.06	543.84	2.69
Retained Earnings	-629.7	-594.29	-470.86	-406.86	-281.89	-152.22
Comprehensive Income & Other	0.38	0.13	-0.15	-	0.01	0.02
Total Common Equity	87.21	103.7	187.6	156.21	261.97	-149.51
Shareholders' Equity	87.21	103.7	187.6	156.21	261.97	73.93
Total Liabilities & Equity	293.58	273.89	351.84	269.31	371.48	147
Total Debt	82.73	85.42	88.75	61.2	61.82	31.64
Net Cash (Debt)	148.13	126.78	193.74	145.13	247.34	93.68
Net Cash Growth	-2.92%	-34.56%	33.50%	-41.32%	164.03%	728.35%
Net Cash Per Share	1.54	1.41	2.69	2.33	6.87	7.42
Filing Date Shares Outstanding	97.47	96.49	86.53	62.55	62.11	13.2
Total Common Shares Outstanding	97.41	95.64	85.96	62.52	61.86	13.2
Working Capital	172.44	155.16	244.68	170.54	283.97	105.32
Book Value Per Share	0.90	1.08	2.18	2.50	4.23	-11.33
Tangible Book Value	81.66	98.15	182.05	150.66	256.42	-155.06
Tangible Book Value Per Share	0.84	1.03	2.12	2.41	4.15	-11.75
Machinery	26.05	23.75	21.06	17.28	13.73	7.97
Construction In Progress	-	-	-	-	0.38	4.73
Leasehold Improvements	14.17	14.11	14.01	13.91	13.83	0.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q